Immunotherapy for urological malignancies

Kent G. Krejci, Mary A. Markiewicz, Eugene D Kwon

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: For decades urologists have successfully used immunotherapy in the battle against cancer. Interleukin-2 in renal cell carcinoma and bacillus Calmette-Guerin in bladder cancer are standard primary and/or adjunctive therapies for these diseases. Recent advances in our understanding of mechanisms governing immune system activation have fostered a myriad of novel immunotherapeutic approaches that show great promise in vivo but have had limited success in human trials to date. This review highlights current immunotherapy strategies that may prove to be successful treatments for urological cancers. Materials and Methods: We performed a MEDLINE literature search for articles relating to immunotherapy in bladder, prostate and renal cell carcinoma in animals and humans. We included the most promising developments in this review. Results: In addition to combining existing therapies to improve their efficacy, novel approaches that attempt to exploit the immune system ability to identify, target and eradicate malignancies are now being developed. These therapies include the use of antitumoral monoclonal and bi-specific antibodies, manipulation of T-lymphocyte costimulatory molecules and the administration of newly discovered cytokines as well as the development of antitumor vaccines. Conclusions: To date the full potential of immunotherapy for the treatment of urological malignancies has not been recognized. As our knowledge of the immune system expands, so too may our ability to manipulate it to affect tumor regression. This review describes the most recent and most promising developments in immunotherapy for urological malignancies.

Original languageEnglish (US)
Pages (from-to)870-876
Number of pages7
JournalJournal of Urology
Volume171
Issue number2 I
DOIs
StatePublished - Feb 2004

Fingerprint

Immunotherapy
Immune System
Neoplasms
Renal Cell Carcinoma
Urologic Neoplasms
Therapeutics
Mycobacterium bovis
Urinary Bladder Neoplasms
MEDLINE
Interleukin-2
Prostate
Urinary Bladder
Vaccines
Cytokines
T-Lymphocytes
Antibodies

Keywords

  • Bladder
  • Immunotherapy
  • Kidney
  • Neoplasms
  • Prostate

ASJC Scopus subject areas

  • Urology

Cite this

Immunotherapy for urological malignancies. / Krejci, Kent G.; Markiewicz, Mary A.; Kwon, Eugene D.

In: Journal of Urology, Vol. 171, No. 2 I, 02.2004, p. 870-876.

Research output: Contribution to journalArticle

Krejci, Kent G. ; Markiewicz, Mary A. ; Kwon, Eugene D. / Immunotherapy for urological malignancies. In: Journal of Urology. 2004 ; Vol. 171, No. 2 I. pp. 870-876.
@article{26e759fc960645949fc4f821b2f9a19e,
title = "Immunotherapy for urological malignancies",
abstract = "Purpose: For decades urologists have successfully used immunotherapy in the battle against cancer. Interleukin-2 in renal cell carcinoma and bacillus Calmette-Guerin in bladder cancer are standard primary and/or adjunctive therapies for these diseases. Recent advances in our understanding of mechanisms governing immune system activation have fostered a myriad of novel immunotherapeutic approaches that show great promise in vivo but have had limited success in human trials to date. This review highlights current immunotherapy strategies that may prove to be successful treatments for urological cancers. Materials and Methods: We performed a MEDLINE literature search for articles relating to immunotherapy in bladder, prostate and renal cell carcinoma in animals and humans. We included the most promising developments in this review. Results: In addition to combining existing therapies to improve their efficacy, novel approaches that attempt to exploit the immune system ability to identify, target and eradicate malignancies are now being developed. These therapies include the use of antitumoral monoclonal and bi-specific antibodies, manipulation of T-lymphocyte costimulatory molecules and the administration of newly discovered cytokines as well as the development of antitumor vaccines. Conclusions: To date the full potential of immunotherapy for the treatment of urological malignancies has not been recognized. As our knowledge of the immune system expands, so too may our ability to manipulate it to affect tumor regression. This review describes the most recent and most promising developments in immunotherapy for urological malignancies.",
keywords = "Bladder, Immunotherapy, Kidney, Neoplasms, Prostate",
author = "Krejci, {Kent G.} and Markiewicz, {Mary A.} and Kwon, {Eugene D}",
year = "2004",
month = "2",
doi = "10.1097/01.ju.0000101161.17279.09",
language = "English (US)",
volume = "171",
pages = "870--876",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2 I",

}

TY - JOUR

T1 - Immunotherapy for urological malignancies

AU - Krejci, Kent G.

AU - Markiewicz, Mary A.

AU - Kwon, Eugene D

PY - 2004/2

Y1 - 2004/2

N2 - Purpose: For decades urologists have successfully used immunotherapy in the battle against cancer. Interleukin-2 in renal cell carcinoma and bacillus Calmette-Guerin in bladder cancer are standard primary and/or adjunctive therapies for these diseases. Recent advances in our understanding of mechanisms governing immune system activation have fostered a myriad of novel immunotherapeutic approaches that show great promise in vivo but have had limited success in human trials to date. This review highlights current immunotherapy strategies that may prove to be successful treatments for urological cancers. Materials and Methods: We performed a MEDLINE literature search for articles relating to immunotherapy in bladder, prostate and renal cell carcinoma in animals and humans. We included the most promising developments in this review. Results: In addition to combining existing therapies to improve their efficacy, novel approaches that attempt to exploit the immune system ability to identify, target and eradicate malignancies are now being developed. These therapies include the use of antitumoral monoclonal and bi-specific antibodies, manipulation of T-lymphocyte costimulatory molecules and the administration of newly discovered cytokines as well as the development of antitumor vaccines. Conclusions: To date the full potential of immunotherapy for the treatment of urological malignancies has not been recognized. As our knowledge of the immune system expands, so too may our ability to manipulate it to affect tumor regression. This review describes the most recent and most promising developments in immunotherapy for urological malignancies.

AB - Purpose: For decades urologists have successfully used immunotherapy in the battle against cancer. Interleukin-2 in renal cell carcinoma and bacillus Calmette-Guerin in bladder cancer are standard primary and/or adjunctive therapies for these diseases. Recent advances in our understanding of mechanisms governing immune system activation have fostered a myriad of novel immunotherapeutic approaches that show great promise in vivo but have had limited success in human trials to date. This review highlights current immunotherapy strategies that may prove to be successful treatments for urological cancers. Materials and Methods: We performed a MEDLINE literature search for articles relating to immunotherapy in bladder, prostate and renal cell carcinoma in animals and humans. We included the most promising developments in this review. Results: In addition to combining existing therapies to improve their efficacy, novel approaches that attempt to exploit the immune system ability to identify, target and eradicate malignancies are now being developed. These therapies include the use of antitumoral monoclonal and bi-specific antibodies, manipulation of T-lymphocyte costimulatory molecules and the administration of newly discovered cytokines as well as the development of antitumor vaccines. Conclusions: To date the full potential of immunotherapy for the treatment of urological malignancies has not been recognized. As our knowledge of the immune system expands, so too may our ability to manipulate it to affect tumor regression. This review describes the most recent and most promising developments in immunotherapy for urological malignancies.

KW - Bladder

KW - Immunotherapy

KW - Kidney

KW - Neoplasms

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=0347759817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347759817&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000101161.17279.09

DO - 10.1097/01.ju.0000101161.17279.09

M3 - Article

C2 - 14713844

AN - SCOPUS:0347759817

VL - 171

SP - 870

EP - 876

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2 I

ER -